Literature DB >> 19413995

N-acylethanolamines, anandamide and food intake.

Harald S Hansen1, Thi Ai Diep.   

Abstract

Anandamide and the other N-acylethanolamines, e.g. oleoylethanolamide (OEA), palmitoylethanolamide (PEA), and linoleoylethanolamide (LEA), may be formed by several enzymatic pathways from their precursors, which are the N-acylated ethanolamine phospholipids. The exact enzymatic pathways involved in their biosynthesis in specific tissues are not clarified. It has been suggested that endogenous anandamide could stimulate food intake by activation of cannabinoid receptors in the brain and/or in the intestinal tissue. On the other hand, endogenous OEA and PEA have been suggested to inhibit food intake by acting on receptors in the intestine. At present, there is no clear role for endogenous anandamide in controlling food intake via cannabinoid receptors, neither centrally nor in the gastrointestinal tract. However, OEA, PEA and perhaps also LEA may be involved in regulation of food intake by selective prolongation of feeding latency and post-meal interval. These N-acylethanolamines seem to be formed locally in the intestine, where they can activate PPARalpha located in close proximity to their site of synthesis. The rapid onset of OEA response and its reliance on an intact vagus nerve suggests that activation of PPARalpha does not result in formation of a transcription-dependent signal but must rely on an unidentified non-genomic signal that translates to activation of vagal afferents. Whether GPR119, TRPV1 and/or intestinal ceramide levels also contribute to the anorectic and weight-reducing effect of exogenous OEA is less clear. Prolonged intake of dietary fat (45 energy%) may promote over-consumption of food by decreasing the endogenous levels of OEA, PEA and LEA in the intestine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19413995     DOI: 10.1016/j.bcp.2009.04.024

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  48 in total

1.  Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice.

Authors:  Angelo A Izzo; Raffaele Capasso; Gabriella Aviello; Francesca Borrelli; Barbara Romano; Fabiana Piscitelli; Laura Gallo; Francesco Capasso; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

3.  Modulation of plasma N-acylethanolamine levels and physiological parameters by dietary fatty acid composition in humans.

Authors:  Peter J H Jones; Lin Lin; Leah G Gillingham; Haifeng Yang; Jaclyn M Omar
Journal:  J Lipid Res       Date:  2014-09-28       Impact factor: 5.922

Review 4.  Fat sensing and metabolic syndrome.

Authors:  Jang H Youn
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

5.  Pitfalls in the sample preparation and analysis of N-acylethanolamines.

Authors:  Christian Skonberg; Andreas Artmann; Claus Cornett; Steen Honoré Hansen; Harald S Hansen
Journal:  J Lipid Res       Date:  2010-05-05       Impact factor: 5.922

6.  CD36 gene deletion decreases oleoylethanolamide levels in small intestine of free-feeding mice.

Authors:  Ana Guijarro; Jin Fu; Giuseppe Astarita; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2009-09-22       Impact factor: 7.658

Review 7.  Upper intestinal lipids regulate energy and glucose homeostasis.

Authors:  Grace W C Cheung; Andrea Kokorovic; Tony K T Lam
Journal:  Cell Mol Life Sci       Date:  2009-06-10       Impact factor: 9.261

8.  Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients.

Authors:  Giovanni Annuzzi; Fabiana Piscitelli; Lucrezia Di Marino; Lidia Patti; Rosalba Giacco; Giuseppina Costabile; Lutgarda Bozzetto; Gabriele Riccardi; Roberta Verde; Stefania Petrosino; Angela A Rivellese; Vincenzo Di Marzo
Journal:  Lipids Health Dis       Date:  2010-04-28       Impact factor: 3.876

9.  Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women.

Authors:  Michel M Joosten; Michiel Gj Balvers; Kitty Cm Verhoeckx; Henk Fj Hendriks; Renger F Witkamp
Journal:  Nutr Metab (Lond)       Date:  2010-06-14       Impact factor: 4.169

10.  Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.

Authors:  Zhongyi Chen; Lilu Guo; Yongqin Zhang; Rosemary L Walzem; Julie S Pendergast; Richard L Printz; Lindsey C Morris; Elena Matafonova; Xavier Stien; Li Kang; Denis Coulon; Owen P McGuinness; Kevin D Niswender; Sean S Davies
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.